Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Earnings Results

Recursion Pharmaceuticals (NASDAQ:RXRX) posted its quarterly earnings data on Wednesday. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01), Briefing.com reports. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter last year, the business posted ($0.43) EPS. The company’s quarterly revenue was up 147.6% on a year-over-year basis.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded down $0.04 during trading on Thursday, hitting $6.93. The stock had a trading volume of 5,743,250 shares, compared to its average volume of 5,667,865. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a 12 month low of $5.03 and a 12 month high of $15.74. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -4.30 and a beta of 0.81. The business’s 50-day moving average is $6.59 and its 200 day moving average is $7.63.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total value of $120,800.00. Following the transaction, the chief executive officer now directly owns 762,656 shares in the company, valued at $4,606,442.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares in the company, valued at $4,606,442.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $6.35, for a total value of $95,250.00. Following the completion of the transaction, the chief financial officer now directly owns 1,340,968 shares in the company, valued at approximately $8,515,146.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 171,682 shares of company stock valued at $1,107,868. Company insiders own 15.75% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on RXRX shares. KeyCorp decreased their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Leerink Partners decreased their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday. Finally, Jefferies Financial Group cut their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.